AETHLON MEDICAL INC
AEMDAethlon Medical Inc. (AEMD) is a biotechnology company focused on developing therapeutic and diagnostic technologies for infectious disease and cancer. The company is known for its Hemopurifier, a device designed to capture and remove viruses, tumor-derived antigens, and other pathogenic substances from the blood. Aethlon aims to address unmet medical needs through its innovative biofiltration and immunotherapy-based platforms.
Company News
Aethlon Medical published preclinical study showing their Hemopurifier device can bind and remove extracellular vesicles from Long COVID patient samples, potentially decreasing inflammatory microRNAs and offering a novel therapeutic approach.
Aethlon Medical reported Q2 2025 financial results, highlighting clinical progress in oncology trials, ongoing Long COVID research, and significant cost reductions of 48% in operating expenses.
Promeza MG has been contracted by AETH to provide marketing services for a theological conference addressing migration, preaching, and pastoral care, taking place in October 2025 at Life Pacific University.
Aethlon Medical has priced a public offering of 5 million shares and warrants at $0.90 per share, expecting to raise approximately $4.5 million for general corporate purposes including clinical trials and research.
Aethlon Medical will release its fiscal Q1 2025 financial results on August 13, hosting a conference call to discuss financial performance and recent corporate developments, focusing on their Hemopurifier medical device for treating cancer and infectious diseases.
